Nuwellis Closes $6M Public Offering
Analysis based on 6 articles · First reported Jun 05, 2026 · Last updated Jun 09, 2026
The successful closing of the public offering by Nuwellis>>> provides the company with additional capital, which can be used for operational expenses, product development, and market expansion, potentially boosting investor confidence in Nuwellis>>>'s future. This influx of funds could stabilize Nuwellis>>>'s financial position and support its growth initiatives in the medical technology sector.
Nuwellis, Inc., a medical technology company, announced the closing of a public offering on June 8, 2026, raising approximately $6.0 million. The offering included 1,903,338 shares of common stock and 18,096,662 pre-funded warrants, each accompanied by Series C Warrants (up to 60,000,000 shares) and Series D Warrants (up to 20,000,000 shares). The public offering price was $0.30 per share and accompanying warrants, and $0.2999 per pre-funded warrant and accompanying warrants. Advisor Group — Ladenburg Thalmann & Co. Inc. served as the sole book-running manager. The securities were offered pursuant to registration statements declared effective by the United States — United States Securities and Exchange Commission. This capital infusion is intended to support Nuwellis's solutions for patients with cardiorenal conditions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard